In one study, ZNF330 was identified as a potential oncogenic factor in breast cancer (Zhang et al., 2021), and we also found that high expression of ZNF330 in PRAD led to worse clinical prognosis, which was associated with the occurrence of PRAD progressive disease (PD), DSS event (Supplementary Figures S2E, F). This evidence concerns the gene NOAZFP and breast carcinoma.